A murine model of targeted infusion for intracranial tumors

Kim, Minhyung; Barone, Tara A.; Fedtsova, Natalia; Gleiberman, Anatoli S.; Wilfong, Chandler; Alosi, Julie A.; Plunkett, Robert J.; Gudkov, Andrei V.; Skitzki, Joseph J.

doi:10.1007/s11060-015-1942-7

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, IA-delivered drugs have often been found unable to penetrate the BBB and their PK still is poorly understood. These studies may take advantage of a recently developed mouse model of IA drug delivery accessing the internal carotid artery to treat ipsilateral implanted HGG tumors (30,42). These studies may take advantage of a recently developed mouse model of IA drug delivery accessing the internal carotid artery to treat ipsilateral implanted HGG tumors (30,42).…”

Section: Intra-arterialmentioning

confidence: 99%

“…Intra-arterial (IA) drug delivery is a physiologically appealing strategy as drugs may be widely distributed throughout the tumor capillary network and high regional tissue concentrations could be achieved with relatively low doses (29). Albeit IA drug administration for HGG has been explored since the 1950s as an attempt to improve drug delivery, the question whether IA administration is safe and more effective compared to other delivery modalities remains open with a number of critical oversights (30). In particular, IA-delivered drugs have often been found unable to penetrate the BBB and their PK still is poorly understood.…”

Section: Intra-arterialmentioning

confidence: 99%

“…Despite those limits, clinical interest in IA drugs for the treatment of HGG persists, linked to improved drug selections and formulations as well as novel methodologies allowing better definition of the HGG morphology and lower treatment-related neurological injury (29). These studies may take advantage of a recently developed mouse model of IA drug delivery accessing the internal carotid artery to treat ipsilateral implanted HGG tumors (30,42).…”

Section: Intra-arterialmentioning

confidence: 99%

See 2 more Smart Citations

Advances in drug delivery to high grade gliomas

Fròsina

2016

Brain Pathology

View full text Add to dashboard Cite

If cancer is hard to be treated, brain cancer is even more, caused by the inability of many effective drugs given systemically to cross the blood brain and blood tumor barriers and reach adequate concentrations at the tumor sites. Effective delivery of drugs to brain cancer tissues is thus a necessary, albeit not sufficient, condition to effectively target the disease. In order to analyze the current status of research on drug delivery to high grade gliomas (HGG-WHO grades III and IV), the most frequent and aggressive brain cancers, a literature search was conducted in PubMed using the terms: "drug delivery and brain tumor" over the publication year 2015. Currently explored drug delivery techniques for HGG include the convection and permeabilization-enhanced deliveries, drug-releasing depots and Ommaya reservoirs. The efficacy/safety ratio widely varies among these techniques and the success of current efforts to increase this ratio widely varies as well.

show abstract

Section: Intra-arterialmentioning

confidence: 99%

Section: Intra-arterialmentioning

confidence: 99%

Section: Intra-arterialmentioning

confidence: 99%

See 1 more Smart Citation

Advances in drug delivery to high grade gliomas

Fròsina

2016

Brain Pathology

View full text Add to dashboard Cite

show abstract

The first endovascular rat glioma model for pre-clinical evaluation of intra-arterial therapeutics

et al. 2023

View full text Add to dashboard Cite

Background Several translational animal models have been described assessing intra-arterial (IA) treatments for malignant gliomas. We describe the first endovascular animal model that allows testing of IA drug delivery as a first-line treatment, which is difficult to do in actual patients. We report a unique protocol for vascular access and IA delivery in the rat model that, unlike prior reports, does not require direct puncture and opening of proximal cerebrovasculature which carries risk of ischemia in the animal brain post-delivery. Methods Wistar rats underwent left femoral artery catherization with a Balt Magic 1.2F catheter or Marathon Flow directed 1.5F Microcatheter with an Asahi Chikai 0.008 micro-guidewire which was navigated to the left internal carotid artery under x-ray. 25% mannitol was administered to test blood brain barrier breakdown (BBBB). Additional rats were implanted with C6 glioma cells in the left frontal lobe. C6 Glioma-Implanted Rats (C6GRs) were monitored for overall survival and tumor growth. Tumor volumes from MRI images were calculated utilizing 3D slicer. Additional rats underwent femoral artery catheterization with Bevacizumab, carboplatin, or irinotecan injected into the left internal carotid artery to test feasibility and safety. Results A successful endovascular access and BBBB protocol was established. BBBB was confirmed with positive Evans blue staining. 10 rats were successfully implanted with C6 gliomas with confirmed growths on MRI. Overall survival was 19.75 ± 2.21 days. 5 rats were utilized for the development of our femoral catheterization protocol and BBBB testing. With regards to IA chemotherapy dosage testing, control rats tolerated targeted 10 mg/kg of bevascizumab, 2.4 mg/kg of carboplatin, and 15 mg/kg of irinotecan IA ICA injections without any complications. Conclusions We present the first endovascular IA rat glioma model that allows selective catheterization of the intracranial vasculature and assessment of IA therapies for gliomas without need for access and sacrifice of proximal cerebrovasculature.

show abstract

A murine model of targeted infusion for intracranial tumors

Cited by 2 publications

References 27 publications

Advances in drug delivery to high grade gliomas

Advances in drug delivery to high grade gliomas

The first endovascular rat glioma model for pre-clinical evaluation of intra-arterial therapeutics

Contact Info

Product

Resources

About